Other experience Through Psephos, since May 2016 Robin has provided strategic and operational regulatory leadership and support to Symetis SA (now Boston Scientific) including coordinating all activities with FDA, Health Canada, etc. as well as being an integral part of the CE Marking team. In May 2017 Symetis was acquired by Boston Scientific for $435 million. Robin has worked with a number of organisations, both in the UK and overseas, including Life Care Medical Devices, Oxymon Limited, Apica Cardiovascular (acquired for $75 million), Conor Medsystems (acquired for $1.4 billion), Medtronic Vascular, Arterial Vascular Engineering (acquired for $3.5 billion) and Global Regulatory Associates Limited.
He is a visiting lecturer at the University of Limerick, a published author on regulatory matters and has been Scientific Advisor to a medical technology publishing house as well as editor of a series of books on biomaterials. Robin regularly presents and teaches at medical device courses and conferences.